Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a medical technology company driving a
fundamental shift in the surgical treatment of bunions and related
midfoot deformities through its flagship Lapiplasty® and
Adductoplasty® Procedures, today announced the first-ever National
Bunion Day in the United States. National Bunion Day is an
opportunity to help more people learn about the identification and
treatment of this common bone deformity in the foot, which often
includes debilitating pain for millions of adults in the U.S.
Approximately one in four U.S. adults alone develop the bunion
deformity in their lifetime.1
As the leader in 3D bunion correction, Treace is
uniquely positioned to drive greater patient education and
awareness of the Lapiplasty® procedure, the #1 most commonly used
3D bunion correction procedure chosen by U.S. surgeons.2 As
part of National Bunion Day, Treace is sponsoring a broad-based
awareness and information campaign to address misconceptions and
stigma associated with bunions. The awareness campaign includes a
series of new educational materials, online events, opportunities
for patients to share their experiences in traditional and social
media, and physician outreach. April also marks National Foot
Health Awareness Month, an opportunity to set a strong foundation
of bunion education and awareness. The month-long effort calls on
all followers to stand up against the stigma surrounding bunions,
fostering a community of support.
“Since our first surgical cases in 2015, Treace
has been committed to developing innovative treatment options for
patients living with bunions and other midfoot deformities, but
issues in foot health and bunion treatment have remained under the
radar despite the fact that they affect millions of people,” said
John T. Treace, CEO and Founder of Treace. “Our establishment of
National Bunion Day is a reflection of our dedication to the
patient communities we serve, and the launch of our new national
campaign is designed to erase the stigma and misinformation
surrounding bunions and to expand our support for both patients and
clinicians through our awareness and educational initiatives. The
Lapiplasty® 3D Bunion Correction® Procedure, pioneered by Treace,
is designed to minimize recovery time, provide lasting relief from
bunion pain, reduce recurrence rates, and improve patient outcomes.
We look forward to reaching even more people and raising awareness
of the impact that effective bunion treatment can have on the
quality of life for patients.”
“Our practice is proud to offer the Lapiplasty®
3D Bunion Correction® Procedure to our patients, who often live
with bunion pain for months or even years because of the stigma
surrounding the condition,” stated Paul Dayton, DPM, MS, FACFAS, of
the Foot & Ankle Center of Iowa and one of the original design
surgeons for the Lapiplasty® Procedure.3 “The establishment of
National Bunion Day will bring attention to this common and
disruptive health issue, educate patients about the latest
treatment options that are designed to get them back to the
activities they enjoy and dismantle the stigma surrounding this
condition.”
Founded by Treace, National Bunion Day will be
held each year on the third Tuesday of April. Updates on activities
planned for National Bunion Day are available on the official
National Bunion Day webpage at
www.lapiplasty.com/NationalBunionDay.
Those living with bunion pain are encouraged to
speak with their healthcare professional about available treatment
plans and whether the Lapiplasty® Procedure is right for them.
Individual results and recovery times may vary. More information
about the Lapiplasty® Procedure, including benefits, risks, and
recovery, is available at https://www.lapiplasty.com/.
About Bunions and the
Lapiplasty® 3D Bunion
Correction® Procedure
Bunions are complex bone deformities that result
from an unstable joint in the midfoot4 and are frequently marked by
a large bump on the side of the big toe. While many believe they
are caused by wearing high heels or narrow shoes, bunions affect
both men and women of all ages and are often caused by genetic
factors.4,5 Bunion deformities are progressive and may lead to
arthritis, hammertoes, bone spurs, pain, swelling and numbness that
may have a significant impact on mobility and quality of life.4,6
Many people may be reluctant to seek treatment for bunions due to
common misconceptions surrounding treatment approaches.
The Lapiplasty® 3D Bunion
Correction® Procedure allows surgeons to correct all three
planes of the bunion deformity and address its root cause by
securing the unstable joint in the middle of the foot using a
patented combination of instruments, implants and surgical methods.
By facilitating a comprehensive, 3D correction of the bunion
deformity, the Lapiplasty® Procedure allows most patients to
quickly return to bearing weight in a surgical boot within two
weeks after surgery and get back to their active lifestyle with a
low recurrence rate of only 0.9% to 3.2% as demonstrated in studies
at 17- and 13-months follow-up, respectively.7,8
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. All statements other than statements of
historical fact are forward-looking statements, including, but not
limited to, the Company’s expectations that it will reach even more
people during National Bunion Day and raise awareness of the impact
that effective bunion treatment can have on the quality of life for
patients. Forward-looking statements are based on management’s
current assumptions and expectations of future events and trends,
which affect or may affect the Company’s business, strategy,
operations or financial performance, and actual results and other
events may differ materially from those expressed or implied in
such statements due to numerous risks and uncertainties.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Factors that could cause actual results or other events to differ
materially from those contemplated in this press release can be
found in the Risk Factors section of Treace’s public filings with
the Securities and Exchange Commission (SEC), including its Annual
Report on Form 10-K for the year ended December 31, 2023, and its
subsequent SEC filings. Because forward-looking statements are
inherently subject to risks and uncertainties, you should not rely
on these forward-looking statements as predictions of future
events. These forward-looking statements speak only as of their
date and, except to the extent required by law, the Company
undertakes no obligation to update these statements, whether as a
result of any new information, future developments or
otherwise.
Internet Posting of
Information
Treace routinely posts information that may be
important to investors in the “Investor Relations” section of its
website at www.treace.com. The Company encourages investors and
potential investors to consult the Treace website regularly for
important information about Treace.
About Treace Medical
Concepts
Treace Medical Concepts, Inc. is a medical
technology company with the goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities. Bunions are complex 3-dimensional deformities that
originate from an unstable joint in the middle of the foot and
affect approximately 67 million Americans, of which Treace
estimates 1.1 million are annual surgical candidates. Treace has
pioneered and patented the Lapiplasty® 3D Bunion
Correction® System – a combination of instruments, implants,
and surgical methods designed to surgically correct all three
planes of the bunion deformity and secure the unstable joint,
addressing the root cause of the bunion and helping patients get
back to their active lifestyles. To further support the needs of
bunion patients, Treace has introduced its
Adductoplasty® Midfoot Correction System, designed for
reproducible surgical correction of the midfoot as well as its
Hammertoe PEEK Fixation System designed to address hammertoe, claw
toe and mallet toe deformities. The Company continues to expand its
footprint in the foot and ankle market with the introduction of its
SpeedPlate™ Rapid Compression Implants, an innovative fixation
platform with broad versatility across Lapiplasty® and
Adductoplasty® procedures, as well as other common bone fusion
procedures of the foot. For more information, please visit
www.treace.com.
To learn more about Treace, connect with us on
LinkedIn, Twitter, Facebook and Instagram.
1 Nix S, et al. J Foot Ankle Res. 2010.
27:3:21.2 TMC Data on File (AOFAS Member Survey August 2023).3 Paul
Dayton, DPM, is a member of Treace’s Surgeon Advisory Board and a
paid consultant for Treace.4 American College of Foot and Ankle
Surgeons (ACFAS) Website5 WebMD Website6 American Academy of
Orthopedic Surgeons (AAOS) Website7 Dayton P, et al. J Foot Ankle
Surg. 2019. 58:427-433. 8 Ray J, et al. Foot Ankle Int. 2019
Aug;40(8):955-960.
Contacts:
Treace Medical Concepts,
Inc.
Julie Dewey, IRCChief Communications &
Investor Relations Officerjddewey@treace.com |
209-613-6945
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/2d0d0b1a-431e-440f-9da7-2ddbbf022a7d
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From Aug 2023 to Aug 2024